Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bay1067197. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 20/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bay1067197 SCHEMBL20211437 | 1.00 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| Bay1067197 SCHEMBL20211436 | 1.00 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| Bay1067197 SCHEMBL20211438 | 1.00 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| Bay1067197 SCHEMBL29376927 | 1.00 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| Bay1067197 SCHEMBL3734456 | 0.99 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| Bay1067197 SCHEMBL20211450 | 0.99 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| Bay1067197 SCHEMBL20211458 | 0.99 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| Bay1067197 SCHEMBL20211454 | 0.99 | ADORA1 (0.57) | ADORA1SLC6A3 | |
| SCHEMBL20211457 | 0.99 | ADORA1 (0.56) | ADORA1SLC6A3 | |
| SCHEMBL20211456 | 0.99 | ADORA1 (0.56) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391620-B1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER IP GMBH (DE) | 2014-05-07 | — | — | EP | claimed |
| WO-2019180072-A1 | PARENTERAL PHARMACEUTICAL COMPOSITION COMPRISING NELADENOSON BIALANATE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-26 | — | — | WO | disclosed |
| EP-3292133-B1 | METHOD FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL) -1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN-6- (PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE HYDROCHLORIDE | Bayer Pharma AG (DE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018108884-A1 | PHARMACEUTICAL TABLET FORMULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | WO | disclosed |
| US-20180155336-A1 | PROCESS FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN0-6-(PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE MONOHYDROCHLORIDE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-07 | — | — | US | disclosed |
| US-20180155336-A1 | PROCESS FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN0-6-(PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE MONOHYDROCHLORIDE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-07 | — | — | US | disclosed |
| EP-2743270-B1 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER IP GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| WO-2015086561-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS AGAINST RENAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-18 | — | — | WO | disclosed |
| US-20140296515-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8772498-B2 | Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2743270-A1 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | Bayer Intellectual Property GmbH (DE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2391620-B1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER IP GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-20130267700-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| US-8420825-B2 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| WO-2010086101-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197609-A1 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS | Bayer Schering Pharma (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267700-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | AADAT, DDC, DNPEP | ADORA1 402/4885SLC6A3 399/4885 |
| US-20100197609-A1 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS | DNPEP, DDC, AADAC | ADORA1 755/4885SLC6A3 687/4885 |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885SLC6A3 1206/4885 |
| US-20180155336-A1 | PROCESS FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN0-6-(PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE MONOHYDROCHLORIDE | PHYKPL, AASDHPPT, PAH | ADORA1 3585/4885SLC6A3 3031/4885 |
| US-20140296515-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | AADAT, DDC, DNPEP | ADORA1 402/4885SLC6A3 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.